Clinical evaluation of GW815SF [salmeterol/fluticasone propionate] for chronic obstructive pulmonary disease (chronic bronchitis, emphysema): assessment of the effect of addition of fluticasone dipropionate to salmeterol xinafoate 50 microg after switching under double-blinded conditions to GW815SF 50/250 microg in chronic obstructive pulmonary disease.

Trial Profile

Clinical evaluation of GW815SF [salmeterol/fluticasone propionate] for chronic obstructive pulmonary disease (chronic bronchitis, emphysema): assessment of the effect of addition of fluticasone dipropionate to salmeterol xinafoate 50 microg after switching under double-blinded conditions to GW815SF 50/250 microg in chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Jan 2005 to Feb 2005 as reported by ClinicalTrials.gov
    • 03 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top